P6.11 THE FRAMINGHAM RISK SCORE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Background: Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular (CV) events and mortality beyond that attributable to smoking. Increased arterial stiffness has been identified in COPD, however it prognostic value has not been established. The Framingham r...

Full description

Bibliographic Details
Main Authors: Nichola Gale*, Margaret Munnery, Ali Albaratti, Dennis Shale, John Cockcroft
Format: Article
Language:English
Published: BMC 2015-11-01
Series:Artery Research
Online Access:https://www.atlantis-press.com/article/125930639/view
_version_ 1818039961026297856
author Nichola Gale*
Margaret Munnery
Ali Albaratti
Dennis Shale
John Cockcroft
author_facet Nichola Gale*
Margaret Munnery
Ali Albaratti
Dennis Shale
John Cockcroft
author_sort Nichola Gale*
collection DOAJ
description Background: Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular (CV) events and mortality beyond that attributable to smoking. Increased arterial stiffness has been identified in COPD, however it prognostic value has not been established. The Framingham risk score provides a validated estimate of an individual’s future CV risk. We hypothesised that patients with COPD would have greater Framingham risk score and aPWV than controls and that aPWV would relate to the Framingham risk score. Methods: At baseline 524 patients with COPD and 143 controls (free from lung disease) were assessed for; lung function (forced expiratory volume (FEV1), forced vital capacity (FVC) and their ratio), BMI, blood pressure (BP) and aPWV. In addition, medical and smoking history were recorded and used to calculate the Framingham risk score and vascular age. Results: Patients and controls were similar in age, gender and BMI, but patients had greater aPWV, Framingham risk score and vascular age which remained after adjustment for age, and MAP. In COPD, Framingham risk related to age r=0.295, aPWV r= 0.234, SBP r=0.194 and FEV1% predicted r=0.112, (all p<0.01). In controls, Framingham risk score related only to age r=0.383, aPWV r=0.189 and systolic BP r=0.195 p<0.05. Conclusions: The association between the Framingham risk score and aPWV suggests that either may be useful to identify individuals with COPD at risk of future CV events. Further follow-up of this cohort will evaluate the prognostic utility of these measures of CV risk.
first_indexed 2024-12-10T08:06:57Z
format Article
id doaj.art-ae05f3ecd1e2409e8c39d99f54c85ebc
institution Directory Open Access Journal
issn 1876-4401
language English
last_indexed 2024-12-10T08:06:57Z
publishDate 2015-11-01
publisher BMC
record_format Article
series Artery Research
spelling doaj.art-ae05f3ecd1e2409e8c39d99f54c85ebc2022-12-22T01:56:39ZengBMCArtery Research1876-44012015-11-011210.1016/j.artres.2015.10.295P6.11 THE FRAMINGHAM RISK SCORE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASENichola Gale*Margaret MunneryAli AlbarattiDennis ShaleJohn CockcroftBackground: Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular (CV) events and mortality beyond that attributable to smoking. Increased arterial stiffness has been identified in COPD, however it prognostic value has not been established. The Framingham risk score provides a validated estimate of an individual’s future CV risk. We hypothesised that patients with COPD would have greater Framingham risk score and aPWV than controls and that aPWV would relate to the Framingham risk score. Methods: At baseline 524 patients with COPD and 143 controls (free from lung disease) were assessed for; lung function (forced expiratory volume (FEV1), forced vital capacity (FVC) and their ratio), BMI, blood pressure (BP) and aPWV. In addition, medical and smoking history were recorded and used to calculate the Framingham risk score and vascular age. Results: Patients and controls were similar in age, gender and BMI, but patients had greater aPWV, Framingham risk score and vascular age which remained after adjustment for age, and MAP. In COPD, Framingham risk related to age r=0.295, aPWV r= 0.234, SBP r=0.194 and FEV1% predicted r=0.112, (all p<0.01). In controls, Framingham risk score related only to age r=0.383, aPWV r=0.189 and systolic BP r=0.195 p<0.05. Conclusions: The association between the Framingham risk score and aPWV suggests that either may be useful to identify individuals with COPD at risk of future CV events. Further follow-up of this cohort will evaluate the prognostic utility of these measures of CV risk.https://www.atlantis-press.com/article/125930639/view
spellingShingle Nichola Gale*
Margaret Munnery
Ali Albaratti
Dennis Shale
John Cockcroft
P6.11 THE FRAMINGHAM RISK SCORE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Artery Research
title P6.11 THE FRAMINGHAM RISK SCORE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
title_full P6.11 THE FRAMINGHAM RISK SCORE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
title_fullStr P6.11 THE FRAMINGHAM RISK SCORE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
title_full_unstemmed P6.11 THE FRAMINGHAM RISK SCORE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
title_short P6.11 THE FRAMINGHAM RISK SCORE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
title_sort p6 11 the framingham risk score in chronic obstructive pulmonary disease
url https://www.atlantis-press.com/article/125930639/view
work_keys_str_mv AT nicholagale p611theframinghamriskscoreinchronicobstructivepulmonarydisease
AT margaretmunnery p611theframinghamriskscoreinchronicobstructivepulmonarydisease
AT alialbaratti p611theframinghamriskscoreinchronicobstructivepulmonarydisease
AT dennisshale p611theframinghamriskscoreinchronicobstructivepulmonarydisease
AT johncockcroft p611theframinghamriskscoreinchronicobstructivepulmonarydisease